Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences
Cidara Therapeutics (Nasdaq: CDTX) has announced its participation in two major investor conferences in November 2024. CEO Jeffrey Stein will present at the Guggenheim Securities Healthcare Innovation Conference on November 11 at 1:30 PM ET in a fireside chat format, which will be available via webcast. The company will also attend the Jefferies London Healthcare Conference from November 19-21.
The Guggenheim presentation will be accessible through a webcast link and remain available for replay on Cidara's website for 90 days. The company, which develops drug-Fc conjugate immunotherapies through its Cloudbreak® platform, will conduct one-on-one investor meetings at both events.
Cidara Therapeutics (Nasdaq: CDTX) ha annunciato la sua partecipazione a due importanti conferenze per investitori nel novembre 2024. Il CEO Jeffrey Stein presenterà alla Guggenheim Securities Healthcare Innovation Conference l'11 novembre alle 13:30 ET in formato colloquiale, disponibile tramite webcast. L'azienda parteciperà anche alla Jefferies London Healthcare Conference dal 19 al 21 novembre.
La presentazione di Guggenheim sarà accessibile tramite un link per webcast e rimarrà disponibile per la riproduzione sul sito web di Cidara per 90 giorni. L'azienda, che sviluppa immunoterapie con coniugati di farmaco-Fc attraverso la sua piattaforma Cloudbreak®, condurrà incontri individuali con gli investitori in entrambi gli eventi.
Cidara Therapeutics (Nasdaq: CDTX) ha anunciado su participación en dos importantes conferencias de inversores en noviembre de 2024. El CEO Jeffrey Stein presentará en la Guggenheim Securities Healthcare Innovation Conference el 11 de noviembre a la 1:30 PM ET en un formato de charla, que estará disponible a través de webcast. La compañía también asistirá a la Jefferies London Healthcare Conference del 19 al 21 de noviembre.
La presentación de Guggenheim será accesible a través de un enlace de webcast y estará disponible para replays en el sitio web de Cidara durante 90 días. La empresa, que desarrolla inmunoterapias con conjugados de fármaco-Fc a través de su plataforma Cloudbreak®, llevará a cabo reuniones individuales con inversores en ambos eventos.
시다라 테라퓨틱스 (Nasdaq: CDTX)는 2024년 11월에 두 개의 주요 투자자 컨퍼런스에 참여할 것이라고 발표했습니다. CEO 제프리 스틴은 구겐하임 증권 헬스케어 혁신 컨퍼런스에서 11월 11일 오후 1시 30분 ET에 파이어사이드 채팅 형식으로 발표할 예정이며, 이 발표는 웹캐스트를 통해 제공됩니다. 회사는 또한 11월 19일부터 21일까지 제프리스 런던 헬스케어 컨퍼런스에 참석할 것입니다.
구겐하임 발표는 웹캐스트 링크를 통해 접근 가능하며, 시다라의 웹사이트에서 90일 동안 다시 볼 수 있습니다. 약물-Fc 결합 면역 요법을 개발하는 이 회사는 두 행사에서 모두 개인 투자자 회의를 진행할 예정입니다.
Cidara Therapeutics (Nasdaq: CDTX) a annoncé sa participation à deux grandes conférences d'investisseurs en novembre 2024. Le PDG Jeffrey Stein présentera à la Guggenheim Securities Healthcare Innovation Conference le 11 novembre à 13h30 ET sous un format de discussion, qui sera disponible en webcast. La société assistera également à la Jefferies London Healthcare Conference du 19 au 21 novembre.
La présentation de Guggenheim sera accessible via un lien de webcast et restera disponible pour rediffusion sur le site de Cidara pendant 90 jours. L'entreprise, qui développe des immunothérapies à conjugats de médicaments-Fc via sa plateforme Cloudbreak®, organisera des réunions individuelles avec les investisseurs lors des deux événements.
Cidara Therapeutics (Nasdaq: CDTX) hat seine Teilnahme an zwei großen Investorenkonferenzen im November 2024 angekündigt. CEO Jeffrey Stein wird am 11. November um 13:30 Uhr ET in einem Fireside-Chat-Format auf der Guggenheim Securities Healthcare Innovation Conference präsentieren, die auch über ein Webcast verfügbar sein wird. Das Unternehmen wird auch an der Jefferies London Healthcare Conference vom 19. bis 21. November teilnehmen.
Die Präsentation von Guggenheim wird über einen Webcast-Link zugänglich sein und für 90 Tage auf der Website von Cidara zum Nachspielen verfügbar bleiben. Das Unternehmen, das über seine Cloudbreak®-Plattform Fc-Konjugat-Immuntherapien entwickelt, wird bei beiden Veranstaltungen Einzelgespräche mit Investoren führen.
- None.
- None.
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the following November investor conferences.
Details are as follows:
Event: Guggenheim Securities Healthcare Innovation Conference
Date: Monday, November 11, 2024
Time: 1:30 PM ET
Format: Fire side chat
Webcast: https://wsw.com/webcast/guggen/cdtx/1949799
A replay of the presentation will be available in the Investors section on the Company’s website at www.cidara.com. The replay of the presentation will be available for 90 days.
Event: Jefferies London Healthcare Conference
Date: Tuesday, November 19 – Thursday, November 21, 2024
Cidara will participate in one-on-one investor meetings during these events. Investors interested in meeting with Cidara at the conferences should contact the appropriate conference directly.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced initiation of a Phase 2b trial in September 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When is Cidara Therapeutics (CDTX) presenting at the Guggenheim Securities Conference in November 2024?
Which investor conferences is Cidara Therapeutics (CDTX) attending in November 2024?
How long will the Guggenheim Conference presentation replay be available for CDTX investors?
What type of presentation format will CDTX use at the Guggenheim Securities Conference?
